Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 174

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies

Open access
Johnson, Douglas B., Lovly, Christine M., Flavin, Marisa, Panageas, Katherine S., Ayers, Gregory D., Zhao, Zhiguo, Iams, Wade T., Colgan, Marta, DeNoble, Sarah, Terry, Charles R., Berry, Elizabeth G., Iafrate, A. John, Sullivan, Ryan J., Carvajal, Richard D., Sosman, Jeffrey A.·2015·Cancer Immunology Research

Abstract

Activating NRAS mutations are found in 15% to 20% of melanomas. Immune therapies have become a mainstay in advanced melanoma treatment. We sought to evaluate whether tumor genotype (e.g., NRAS mutations) correlates with benefit from immune therapy in melanoma. We identified 229 patients with melanoma treated with immune therapies [IL2, ipilimumab, or anti-programmed cell death-1/ligand-1 (PD-1/PD-L1)] at three centers and compared clinical outcomes following immune therapy for patients with or without NRAS mutations. Of the 229 patients with melanoma, 60 had NRAS mutation, 53 had BRAF mutation, and 116 had NRAS/BRAF wild type. The NRAS-mutant cohort had superior or a trend to superior outcomes compared with the other cohorts in terms of response to first-line immune therapy (28% vs. 16%, P = 0.04), response to any line of immune therapy (32% vs. 20%, P = 0.07), clinical benefit (response + stable disease lasting ≥24 weeks; 50% vs. 31%, P < 0.01), and progression-free survival (median, 4.1 vs. 2.9 months, P = 0.09). Benefit from anti–PD-1/PD-L1 was particularly marked in the NRAS cohort (clinical benefit rate 73% vs. 35%). In an independent group of patient samples, NRAS-mutant melanoma had higher PD-L1 expression (although not statistically significant) compared with other genotypes (8/12 vs. 9/20 samples with ≥1% expression; 6/12 vs. 6/20 samples with ≥5% expression), suggesting a potential mechanism for the clinical results. This retrospective study suggests that NRAS mutations in advanced melanoma correlate with increased benefit from immune-based therapies compared with other genetic subtypes. If confirmed by prospective studies, this may be explained in part by high rates of PD-L1 expression. Cancer Immunol Res; 3(3); 288–95. ©2015 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-14-0207

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 174

Metadata

Authors
Johnson, D. B., Lovly, C. M., Flavin, M., Panageas, K. S., Ayers, G. D., Zhao, Z., Iams, W. T., Colgan, M., DeNoble, S., Terry, C. R., Berry, E. G., Iafrate, A. J., Sullivan, R. J., Carvajal, R. D., & Sosman, J. A.
Venue
Cancer Immunology Research
Published
2015-03-01
Volume
3
Issue
3
Pages
288-295
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2089536793
Cited by
174
References
5
FWCI
8.84
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies. https://app.cochat.ai/papers/10.1158/2326-6066.cir-14-0207
The paper
Johnson, D. B., Lovly, C. M., Flavin, M., Panageas, K. S., Ayers, G. D., Zhao, Z., Iams, W. T., Colgan, M., DeNoble, S., Terry, C. R., Berry, E. G., Iafrate, A. J., Sullivan, R. J., Carvajal, R. D., & Sosman, J. A. (2015). Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-14-0207

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.